Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression
Recruiting
Phase 2
Phase 3
Interventional Study
SSTR Positive Tumors
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 400 (estimated)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with SSTR positive tumors
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with suspected or clearly diagnosed SSTR positive tumors
* signed written consent.
* Willing and able to cooperate with all projects in this study.
Exclusion Criteria:
* pregnancy;
* breastfeeding;
* any medical condition that in the opinion of the investigator may …
Contacts